PDCD1 and non-small cell lung carcinoma: PD-L1 expression levels have been of special interest since patients with non-small cell lung cancers (NSCLC) who demonstrate higher levels of expression tend to respond more favorably to the evolving PD-1 and PD-L1 inhibitors [20,21,22].